Загрузка...
Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactori...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Microbiology
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3535933/ https://ncbi.nlm.nih.gov/pubmed/23147724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01611-12 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|